Abel Hall LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Abel Hall LLC’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$217K	Buy	+286	New	+$216K	0.04%	649

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

MCI

McDonald Capital Investors Orinda, California $1.22B AUM 4.07% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Abel Hall LLC's REGN Position: Q3 2026 in Review

Abel Hall LLC opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 286 shares worth $217K. The stake represents 0.04% of the portfolio and ranks #649 among its holdings.

522 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Abel Hall LLC held 286 shares of Regeneron Pharmaceuticals worth $217K as of Q3 2026.
Regeneron Pharmaceuticals was a new Abel Hall LLC position in Q3 2026.
Regeneron Pharmaceuticals made up 0.04% of Abel Hall LLC's portfolio in Q3 2026, its #649 holding.
522 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.